JP2009502777A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502777A5
JP2009502777A5 JP2008522170A JP2008522170A JP2009502777A5 JP 2009502777 A5 JP2009502777 A5 JP 2009502777A5 JP 2008522170 A JP2008522170 A JP 2008522170A JP 2008522170 A JP2008522170 A JP 2008522170A JP 2009502777 A5 JP2009502777 A5 JP 2009502777A5
Authority
JP
Japan
Prior art keywords
tumors
compound
group
compound according
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008522170A
Other languages
English (en)
Other versions
JP2009502777A (ja
JP5312026B2 (ja
Filing date
Publication date
Priority claimed from IT000389A external-priority patent/ITRM20050389A1/it
Application filed filed Critical
Publication of JP2009502777A publication Critical patent/JP2009502777A/ja
Publication of JP2009502777A5 publication Critical patent/JP2009502777A5/ja
Application granted granted Critical
Publication of JP5312026B2 publication Critical patent/JP5312026B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (13)

  1. 一般式(I)の化合物
    Figure 2009502777

    [式中、
    及びRは、同一でも異なってもよく、−H又は1〜6個の炭素原子を有する直鎖又は分枝アルキル基を含む群から選択されるか、一緒になって5個又は6個の原子の芳香族又は脂肪族環を形成しており;
    Y及びZは、同一でも異なってもよく、−H、−OH、−COOH、−OR、−CH(OR)COOHを含む群から選択され、ここでRは、H、フェニル、ベンジル、−CF又は−CFCF、ビニル、アリル及び1〜6個の炭素原子を有する直鎖又は分枝アルキル基から選択される]。
  2. 一般式(Ia)の化合物
    Figure 2009502777

    [式中、
    及びRは、同一でも異なってもよく、−H又は1〜6個の炭素原子を有する直鎖又は分枝アルキル基を含む群から選択され;
    Y及びZは、同一でも異なってもよく、−H、−OH、−COOH、−OR、−CH(OR)COOHを含む群から選択され、ここでRは、−H及び1〜6個の炭素原子を有する直鎖又は分枝アルキル基から選択される]である、請求項1に記載の化合物。
  3. 1〜6個の炭素原子を有する直鎖又は分枝アルキル基が、−CH、−CHCH、−CH(CH、−CHCHCH、−C2n−1 (nは炭素の数である)から選択される、請求項1又は請求項2に記載の化合物。
  4. YがH又は−COOHである、請求項1から3までのいずれか一項に記載の化合物。
  5. Zが−CH(OR)COOHである、請求項1から4までのいずれか一項に記載の化合物。
  6. −CH CH −CH 又は−Hである、請求項1から5までのいずれか一項に記載の化合物。
  7. 化合物が、
    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    を含む群から選択される、請求項1から6までのいずれか一項に記載の化合物。
  8. 鏡像異性的に純粋なR型又はS型をしている、請求項1からまでのいずれか一項に記載の化合物。
  9. ±)−2−ヒドロキシ−2−(3’−アミノフェニル)酢酸
    (±)−2−ヒドロキシ−2−(4’−アミノフェニル)酢酸
    (±)−2−ヒドロキシ−3−(4’−アミノフェニル)プロピオン酸
    (±)−2−メトキシ−3−(3’−アミノフェニル)プロピオン酸
    (±)−2−メトキシ−3−(4’−アミノフェニル)プロピオン酸
    を含む群から選択される化合物を含む、癌性腫瘍又は慢性炎症性疾患の治療の為の医薬品。
  10. 有効成分として請求項1からまでのいずれか一項に記載の1つ又は複数の化合物を1つ又は複数の薬学的に許容できる賦形剤又は補助剤と組合せて含む薬剤組成物。
  11. PPARγ受容体及びEGF受容体を発現する腫瘍の予防及び治療のための請求項1からまでのいずれか一項に記載の化合物を含み、腫瘍が、食道の腫瘍、胃の腫瘍、膵臓の腫瘍、結腸の腫瘍、前立腺の腫瘍、乳房の腫瘍、子宮及び付属器の腫瘍、腎臓の腫瘍並びに肺の腫瘍を含む群から選択される、薬剤組成物。
  12. クローン病及び潰瘍性結腸大腸炎を含む慢性炎症性疾患治療用の請求項1からまでのいずれか一項に記載の化合物を含む医薬品
  13. 化合物が、1つの鏡像異性体が任意の割合で他を超えている混合物中にある、請求項9、11又は12に記載の医薬品
JP2008522170A 2005-07-22 2006-07-24 Ppar受容体及びegf受容体に特異的な化合物及びそれらの塩並びに医療分野におけるそれらの使用 Active JP5312026B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000389A ITRM20050389A1 (it) 2005-07-22 2005-07-22 Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM2005A000389 2005-07-22
PCT/IE2006/000078 WO2007010516A2 (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field

Publications (3)

Publication Number Publication Date
JP2009502777A JP2009502777A (ja) 2009-01-29
JP2009502777A5 true JP2009502777A5 (ja) 2009-10-01
JP5312026B2 JP5312026B2 (ja) 2013-10-09

Family

ID=37579831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522170A Active JP5312026B2 (ja) 2005-07-22 2006-07-24 Ppar受容体及びegf受容体に特異的な化合物及びそれらの塩並びに医療分野におけるそれらの使用

Country Status (23)

Country Link
US (6) US8153841B2 (ja)
EP (1) EP1910270B3 (ja)
JP (1) JP5312026B2 (ja)
KR (1) KR101317519B1 (ja)
CN (2) CN102020577B (ja)
AU (1) AU2006271165C1 (ja)
CA (1) CA2616146C (ja)
CY (1) CY1114294T1 (ja)
DK (1) DK1910270T6 (ja)
EA (2) EA017566B1 (ja)
ES (1) ES2421260T7 (ja)
HR (1) HRP20130549T4 (ja)
IL (2) IL188878A (ja)
IT (1) ITRM20050389A1 (ja)
MX (1) MX366596B (ja)
NO (1) NO340680B1 (ja)
NZ (2) NZ566045A (ja)
PL (1) PL1910270T6 (ja)
PT (1) PT1910270E (ja)
SI (1) SI1910270T1 (ja)
UA (1) UA100359C2 (ja)
WO (1) WO2007010516A2 (ja)
ZA (2) ZA200801671B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
UA107562C2 (uk) * 2008-12-05 2015-01-26 Спосіб лікування псоріазу
UA105037C2 (uk) * 2009-02-16 2014-04-10 Джуліані Інтернешнл Лімітед Способи лікування патологічних станів, пов'язаних з волоссям
EP2578573A4 (en) 2010-05-24 2014-08-06 Toa Eiyo Ltd CONDENSATE IMIDAZOLE DERIVATIVE
JP6301844B2 (ja) * 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
NZ631049A (en) 2012-04-18 2017-02-24 Nogra Pharma Ltd Methods of treating lactose intolerance
JP6496302B2 (ja) * 2014-03-20 2019-04-03 京セラ株式会社 ユーザ端末、通信制御方法及び基地局
WO2017093444A1 (en) * 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
US20220000818A1 (en) 2019-01-25 2022-01-06 Nogra Pharma Limited Compositions for use in preventing acne
MX2021009498A (es) * 2019-02-08 2021-09-08 Nogra Pharma Ltd Proceso de elaboracion de acido 3-(4'-aminofenil)-2-metoxipropioni co y analogos e intermediarios del mismo.

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) * 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) * 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) * 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) * 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en) * 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
EP0055689B1 (de) 1980-12-22 1984-07-04 Schering Aktiengesellschaft In 3-Stellung substituierte 2,4,6-trihalogenierte Benzamide und deren Salze, deren Herstellung und Verwendung als Ersatzstoffe für natürliche Süssstoffe sowie Süssungsmittel auf Basis dieser Verbindungen
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
EP0279096B1 (en) * 1987-02-05 1993-07-07 Kureha Kagaku Kogyo Kabushiki Kaisha Benzyl ether compound and process for producing the same
AU1388388A (en) 1987-04-01 1988-10-06 Dak-Laboratoriet A/S Benzoic acid derivatives and use thereof
DE68919009T2 (de) 1988-05-05 1995-02-23 Tillotts Pharma Ag Verwendung von 5-Amino-salicylsäure für die Behandlung von Hautkrankheiten.
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
JP3425441B2 (ja) 1990-10-22 2003-07-14 ガストロ サービシイズ ピーティーワイ リミテッド 非炎症性及び非感染性腸障害の処置
US5262549A (en) * 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
WO1994000135A1 (en) 1992-06-30 1994-01-06 Shapiro Howard K Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
US5594151A (en) * 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
AU698881B2 (en) 1994-05-11 1998-11-12 Howard K. Shapiro Compositions for treatment of chronic inflammatory diseases
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
HUP9900309A3 (en) 1995-03-28 1999-11-29 Janssen Pharmaceutica Nv Use of ridogrel for producing pharmaceutical compositions for the treatment of inflammatory bowel diseases
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) * 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
WO1998043081A1 (en) 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
WO1999005161A1 (en) * 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
WO1999015520A1 (fr) * 1997-09-19 1999-04-01 Ono Pharmaceutical Co., Ltd. Composes de benzene fusionnes ou non fusionnes
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
US20040034067A1 (en) * 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
DE60013491T2 (de) 2000-04-19 2005-09-01 Neurotech Co., Ltd., Suwon Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems
PT1285908E (pt) * 2000-05-29 2008-12-04 Kyorin Seiyaku Kk Derivados do ácido fenilpropiónico substituídos
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
AU8531101A (en) 2000-08-29 2002-03-13 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
CA2430846A1 (en) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Substituted carboxylic acid derivatives
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
EP1389044A4 (en) 2001-04-18 2006-07-05 Merck & Co Inc PPAR-ALPHA-GAMMA AGONISTS OR LIGANDS FOR THE TREATMENT OF INFLAMMATIONS
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
JP2005527480A (ja) * 2001-10-16 2005-09-15 ドクター・レディーズ・ラボラトリーズ・リミテッド ベンゾキサジンおよびベンゾチアジン誘導体、ならびにそれを含有する医薬組成物
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) * 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) * 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
WO2004082715A1 (ja) * 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
ATE455772T1 (de) 2003-07-21 2010-02-15 Merck Serono Sa Alkinylarylcarbonsäureamide
WO2005039590A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
US20070093476A1 (en) * 2003-10-28 2007-04-26 Bhunia Debnath Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
WO2005055933A2 (en) 2003-12-03 2005-06-23 Smithkline Beecham Corporation Treatment of psoriasis with rosiglitazone
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
WO2005084658A1 (en) 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) * 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
WO2009025854A1 (en) 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
UA105037C2 (uk) 2009-02-16 2014-04-10 Джуліані Інтернешнл Лімітед Способи лікування патологічних станів, пов'язаних з волоссям
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
EP2731605A4 (en) 2011-07-15 2015-02-25 Sla Pharma Ag PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION
EP2773378B1 (en) 2011-10-31 2016-08-10 Larsen, Claus Selch Prodrugs of non-steroid anti-inflammatory agents (nsaids)
JP6301844B2 (ja) * 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
NZ631049A (en) 2012-04-18 2017-02-24 Nogra Pharma Ltd Methods of treating lactose intolerance
CN104619687A (zh) 2012-06-01 2015-05-13 诺格拉制药有限公司 能够调节t-细胞应答的双环杂环及其使用方法
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
US20150250749A1 (en) 2012-09-13 2015-09-10 Nogra Pharma Limited Methods of treating hair related conditions
CA2883836A1 (en) 2012-09-13 2014-03-20 Nogra Pharma Limited Methods of inhibiting hair growth
WO2016154730A1 (en) 2015-04-02 2016-10-06 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
EP3307262B1 (en) 2015-06-15 2021-05-19 NMD Pharma A/S Compounds for use in treating neuromuscular disorders

Similar Documents

Publication Publication Date Title
JP2009502777A5 (ja)
CN110105200B (zh) 用于治疗纤维化的经取代的芳族化合物及相关方法
JP2010532768A5 (ja)
JP2009242409A5 (ja)
JP2009502775A5 (ja)
JP2010540555A5 (ja)
JP2010500293A5 (ja)
JP2010522710A5 (ja)
JP2010077141A5 (ja)
JP2016534063A5 (ja)
JP2011518202A5 (ja)
JP2013519632A5 (ja)
JP2010523476A5 (ja)
JP2011051993A5 (ja)
JP2004514663A5 (ja)
JP2010530881A5 (ja)
JP2012525393A5 (ja)
JP2009530398A5 (ja)
JP2010090149A5 (ja)
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
JP2008542386A5 (ja)
JP2011502174A5 (ja)
JP2015535831A5 (ja)
JP2013511556A5 (ja)
JP2010189446A (ja) 肝臓癌の発症予防のための医薬